Changes and Prognostic Value of Serum Vascular Endothelial Growth Factor in Patients with Differentiated Thyroid Cancer

Overview

Journal Med Princ Pract

Publisher Karger

Specialties General Medicine
Medical Education

Date 2012 Aug 15

PMID 22890443

Citations 6

Authors

Zhen-Hu Zhou

Xiao-Ning Cui

Huai-Guang Xing

Rui-Hong Yan

Dao-Kuo Yao

Le-Xin Wang

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the changes and the prognostic value of serum vascular endothelial growth factor (VEGF) in patients with differentiated thyroid cancer (DTC).

Subjects And Methods: A total of 79 patients with DTC and 30 healthy individuals were divided into four groups: (1) a healthy control group (n = 30); (2) DTC without recurrence (n = 35; 23 papillary, 12 follicular); (3) DTC with local recurrence (n = 24; 15 papillary, 9 follicular), and (4) DTC with lung metastasis (n = 20; 13 papillary, 7 follicular). Serum VEGF and thyroglobulin levels were measured in all patients.

Results: Serum levels of VEGF were significantly higher in the lung metastasis group than in the other three groups (p < 0.05). Serum thyroglobulin concentration positively correlated with VEGF expression (r = 0.8678, p < 0.001) in patients with thyroid cancer recurrence. Multivariate Cox regression analysis showed that clinical staging (OR = 1.851, 95% CI 1.04-3.47; p = 0.038), noncompliance with postoperative thyroxin replacement therapy (OR = 1.935, 95% CI 1.03-3.65; p = 0.042) and postoperative levels of thyroglobulin (OR = 1.892, 95% CI 1.01-3.56, p = 0.032) were independent predictors for thyroid cancer recurrence. Every additional 100 ng/l of serum VEGF levels increased the risk of thyroid cancer recurrence by 20.3%; but this did not reach statistical significance (OR = 1.203, 95% CI 0.95-1.52; p = 0.125).

Conclusions: Serum VEGF increased in patients with recurrent thyroid cancer following surgical therapies. The predictive value of serum VEGF requires further investigation.

Citing Articles

Identification of soluble tissue-derived biomarkers from human thyroid tissue explants maintained on a microfluidic device.

Riley A, Jones H, England J, Kuvshinov D, Green V, Greenman J Oncol Lett. 2021; 22(5):780.

PMID: 34594421 PMC: 8456457. DOI: 10.3892/ol.2021.13041.

Expression of Vascular Endothelial Growth Factor and Its Receptors in Thyroid Nodular Hyperplasia and Papillary Thyroid Carcinoma: A Tertiary Health Care Centre Based Study.

Mohamad Pakarul Razy N, Wan Abdul Rahman W, Win T Asian Pac J Cancer Prev. 2019; 20(1):277-282.

PMID: 30678450 PMC: 6485559. DOI: 10.31557/APJCP.2019.20.1.277.

Evaluation of Serum Vascular Adhesion Protein-1 as a Potential Biomarker in Thyroid Cancer.

Hu Z, Zhao P, Zhang K, Zang L, Liao H, Ma W Int J Endocrinol. 2016; 2016:6312529.

PMID: 27446209 PMC: 4942652. DOI: 10.1155/2016/6312529.

VEGF-D and A Preoperative Serum Levels Predict Nodal and Distant Metastases in Differentiated Thyroid Cancer Patients.

Lai C, Duh Q, Chen C, Chuang F, Chang Y, Lin M World J Surg. 2015; 39(7):1742-9.

PMID: 25670042 DOI: 10.1007/s00268-015-3016-6.

Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM).

Krauze A, Won M, Graves C, Corn B, Muanza T, Howard S Biomark Res. 2013; 1(1):29.

PMID: 24252135 PMC: 4177620. DOI: 10.1186/2050-7771-1-29.

References

Milano A, Chiofalo M, Basile M, Salzano de Luna A, Pezzullo L, Caponigro F . New molecular targeted therapies in thyroid cancer. Anticancer Drugs. 2006; 17(8):869-79. DOI: 10.1097/01.cad.0000224449.16329.c5. View

Klubo-Gwiezdzinska J, Junik R, Kopczynska E, Juraniec O, Kardymowicz H . The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter. Eur J Endocrinol. 2007; 157(4):521-7. DOI: 10.1530/EJE-07-0252. View

Soh E, Duh Q, Sobhi S, Young D, Epstein H, Wong M . Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab. 1997; 82(11):3741-7. DOI: 10.1210/jcem.82.11.4340. View

Karaca Z, Tanriverdi F, Unluhizarci K, Ozturk F, Gokahmetoglu S, Elbuken G . VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2010; 164(2):277-84. DOI: 10.1530/EJE-10-0967. View

Segal K, Shpitzer T, Feinmesser M, Stern Y, Feinmesser R . Angiogenesis in follicular tumors of the thyroid. J Surg Oncol. 1996; 63(2):95-8. DOI: 10.1002/(SICI)1096-9098(199610)63:2<95::AID-JSO5>3.0.CO;2-J. View

Sherman S . Targeted therapies for thyroid tumors. Mod Pathol. 2011; 24 Suppl 2:S44-52. DOI: 10.1038/modpathol.2010.165. View

Sherman S, Wirth L, Droz J, Hofmann M, Bastholt L, Martins R . Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008; 359(1):31-42. DOI: 10.1056/NEJMoa075853. View

Mitsuhashi A, Suzuka K, Yamazawa K, Matsui H, Seki K, Sekiya S . Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer. 2005; 103(4):724-30. DOI: 10.1002/cncr.20819. View

Tamura M, Ohta Y . Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer. 2003; 98(6):1217-22. DOI: 10.1002/cncr.11529. View

10.

Tuttle R, Fleisher M, Francis G, Robbins R . Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab. 2002; 87(4):1737-42. DOI: 10.1210/jcem.87.4.8388. View

11.

Hsueh C, Lin J, Wu I, Chao T, Yu J, Liou M . Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma. J Surg Oncol. 2011; 103(5):395-9. DOI: 10.1002/jso.21844. View

12.

Katoh R, Miyagi E, Kawaoi A, Hemmi A, Komiyama A, Oyama T . Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Pathol. 1999; 30(8):891-7. DOI: 10.1016/s0046-8177(99)90241-1. View

13.

Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F . Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene. 1995; 11(8):1569-79. View

14.

Nersita R, Matrone A, Klain M, Scavuzzo F, Vitolo G, Abbondanza C . Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2011; 76(1):142-6. DOI: 10.1111/j.1365-2265.2011.04183.x. View

15.

Dhar D, Kubota H, Kotoh T, Tabara H, Watanabe R, Tachibana M . Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. Am J Surg. 1999; 176(5):442-7. DOI: 10.1016/s0002-9610(98)00238-4. View

16.

Ishiwata I, Sudo T, Kiguchi K, Ishikawa H . Tumor angiogenesis factors produced by cancer cells. Hum Cell. 1999; 12(1):37-46. View

17.

Karayiannakis A, Syrigos K, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C . Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg. 2002; 236(1):37-42. PMC: 1422546. DOI: 10.1097/00000658-200207000-00007. View

18.

Yu X, Lo C, Chan W, Lam K, Leung P, Luk J . Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res. 2005; 11(22):8063-9. DOI: 10.1158/1078-0432.CCR-05-0646. View

19.

Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D . Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene. 1997; 15(22):2687-98. DOI: 10.1038/sj.onc.1201456. View

20.

Itoh A, Iwase K, Jimbo S, Yamamoto H, Yamamoto N, Kokubo M . Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders. World J Surg. 2009; 34(2):242-8. DOI: 10.1007/s00268-009-0344-4. View